The need for strategies to address obesity and psoriatic arthritis prevention in psoriasis

Ogdie, Alexis; Eder, Lihi

doi:10.1111/bjd.18595

Cited by 5 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that some of this improvement is driven by the patient-reported outcomes (PROs) as patients generally feel better after weight loss. However, regardless of why the improvement in achievement of MDA occurs, there is a need for weight reduction strategies to improve clinical outcomes for our patients [ 52 , 53 ].…”

Section: Impact Of Obesity On Response To Therapymentioning

confidence: 99%

“…However, there are currently relatively few resources for rheumatologists and dermatologists to help patients lose weight. Access to nutritionists to guide dietary interventions is desirable but not always available [ 53 ]. Physical activity recommendations for patients with inflammatory arthritis are the same as for the general population [ 63 ].…”

Section: Manage Obesity In Patients With Psamentioning

confidence: 99%

See 1 more Smart Citation

Obesity and Psoriatic Arthritis: A Narrative Review

Kumthekar

Ogdie

2020

Rheumatol Ther

View full text Add to dashboard Cite

Patients with psoriatic arthritis (PsA) have a higher burden of cardio-metabolic comorbidities like obesity, hypertension, diabetes, and cardiovascular disease compared to the general population. Adipose tissue is thought to promote a chronic low grade inflammatory state through inflammatory mediators like tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), leptin, and adiponectin. A higher body mass index (BMI) is a risk factor for development of PsA and affects disease activity and response to therapy including both disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor inhibitors (TNFi). Obesity has an impact on the morbidity in PsA, particularly cardiovascular and/or metabolic. Patients with PsA have a higher cardiovascular risk and obesity may have an additive impact on morbidity and mortality. This review explores the relationship between obesity and PsA.

show abstract

Section: Impact Of Obesity On Response To Therapymentioning

confidence: 99%

Section: Manage Obesity In Patients With Psamentioning

confidence: 99%

Obesity and Psoriatic Arthritis: A Narrative Review

Kumthekar

Ogdie

2020

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

“…Tailored illness‐specific weight‐loss interventions that address psychosocial difficulties, including emotional and behavioural issues, provide a more balanced approach to weight loss 15,16 . Thus, they may be more effective in supporting weight loss than generic ones and ultimately lead to better weight loss and psychological outcomes 17,18 …”

Section: Introductionmentioning

confidence: 99%

“…15,16 Thus, they may be more effective in supporting weight loss than generic ones and ultimately lead to better weight loss and psychological outcomes. 17,18 A recent systematic review highlighted that none of the weight-loss interventions in psoriasis included consideration of psychological or social factors. 19 Instead, general models of weight loss such as lowcalorie interventions embedded in pharmacological treatments were used.…”

mentioning

confidence: 99%

Psychosocial aspects of obesity in adults with psoriasis: A systematic review

Pavlova

Kioskli

Smith

et al. 2021

Skin Health and Disease

View full text Add to dashboard Cite

Background: Excess weight is a common (30%-40%) multifactorial concern that remains understudied in adults with psoriasis. Objectives: This systematic review aimed to synthesise the evidence on the psychosocial factors associated with body weight in psoriasis and to use these findings to inform clinical practice. The review was registered with PROSPERO (registration number: CRD42020201138). Methods: Electronic databases, related reviews and associated reference lists were searched. Observational and experimental studies reporting on the relationship of psychosocial factors to weight-related outcomes in adults with body mass index (BMI) of ≥30 kg/m 2 and psoriasis were eligible. The methodological quality of the included studies was assessed using the Critical Appraisal Skills Programme (CASP). Results: Eighteen studies were included in the review, the majority of which (n = 16) examined cross-sectional associations between psychosocial factors and weight outcomes. Although the strengths of the associations were heterogeneous, most studies confirmed the positive association between high BMI and increased reports of depression and anxiety, impaired quality of life, deteriorated sleep quality, sexual dysfunction, and daily functioning issues. Only four studies were rated as high quality. Conclusions: The current evidence of the association between psychosocial factors and weight-related outcomes is largely cross-sectional with unclear directionality of causality. Longitudinal studies are needed to examine the replicability and generalisability of the examined obesity-related psychosocial factors in psoriasis. Theoretical exploration of subgroup differences and similarities may pave the way towards intervention personalisation, and ultimately, improved patient outcomes. K E Y W O R D S psoriasis, psychodermatology, quality of life | INTRODUCTIONPsoriasis and obesity are major public health issues, both on the rise. 1,2 Psoriasis is a debilitating inflammatory systemic disease, affecting an estimated 29.5 million adults worldwide and about 1 million in the UK population. 2 A third of people living with psoriasis are obese, defined as a body mass index (BMI) ofThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Les patients atteints de psoriasis et de RPso sont plus fréquemment obèses que la population générale et que les PR [13,14]. L'obésité est un facteur de risque pour le psoriasis et le RPso.…”

Section: C-obésitéunclassified